Adnectins: engineered target-binding protein therapeutics - Wikidata - awgldk - TriplyDB

Adnectins: engineered target-binding protein therapeutics

Adnectins: engineered target-binding protein therapeutics

http://www.wikidata.org/entity/Q33743756

about

Intracellular targeting with engineered proteins Applications of Yeast Surface Display for Protein Engineering Hydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeutics Monoclonal antibodies for the treatment of cancer Teaching an Old Scaffold New Tricks: Monobodies Constructed Using Alternative Surfaces of the FN3 Scaffold Selection of Specific Protein Binders for Pre-Defined Targets from an Optimized Library of Artificial Helicoidal Repeat Proteins (alphaRep)Structural Similarity between Defense Peptide from Wheat and Scorpion Neurotoxin Permits Rational Functional Design C-terminal β-strand swapping in a consensus-derived fibronectin Type III scaffold A current perspective on applications of macrocyclic-peptide-based high-affinity ligands Extremophilic 50S Ribosomal RNA-Binding Protein L35Ae as a Basis for Engineering of an Alternative Protein Scaffold Derivative of Extremophilic 50S Ribosomal Protein L35Ae as an Alternative Protein Scaffold Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Anti-idiotypic monobodies derived from a fibronectin scaffold.Engineering of monobody conjugates for human EphA2-specific optical imaging.Tetraspecific ligand for tumor-targeted delivery of nanomaterials.Structural basis of IL-23 antagonism by an Alphabody protein scaffold Peptide aptamers: development and applications.The influence of adnectin binding on the extracellular domain of epidermal growth factor receptor.Epitope-guided engineering of monobody binders for in vivo inhibition of Erk-2 signaling.Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2.Small-molecule modulators of the constitutive androstane receptor.High-Throughput Ligand Discovery Reveals a Sitewise Gradient of Diversity in Broadly Evolved Hydrophilic Fibronectin Domains Streamlining the Pipeline for Generation of Recombinant Affinity Reagents by Integrating the Affinity Maturation Step.A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering.ANTICALIgN: visualizing, editing and analyzing combined nucleotide and amino acid sequence alignments for combinatorial protein engineering.Designed hydrophilic and charge mutations of the fibronectin domain: towards tailored protein biodistribution.Titratable Avidity Reduction Enhances Affinity Discrimination in Mammalian Cellular Selections of Yeast-Displayed Ligands.Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis.Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.Circumventing the stability-function trade-off in an engineered FN3 domain Alternative Non-Antibody Protein Scaffolds for Molecular Imaging of Cancer RECRUIT-TandAbs: harnessing the immune system to kill cancer cells.PCSK9 Inhibitors: potential in cardiovascular therapeutics.Design and evaluation of radiolabeled tracers for tumor imaging.Development of proteome-wide binding reagents for research and diagnostics.Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development.The integration of ligand binding and LC-MS-based assays into bioanalytical strategies for protein analysis.Antibody mimetics: promising complementary agents to animal-sourced antibodies.

P2860

Q26740106-0A550B22-103D-4316-BABB-5DD8F6C51485 Q26823830-944E9487-3019-49D2-A72C-A11E792AB9A2 Q27004640-519E777F-0107-4D0C-A5BB-90CC017E78B0 Q27025966-A672CF27-56B8-4FE6-96BA-A736EC9B0633 Q27676439-06C7316F-9C6A-4444-B548-2414179F8EE3 Q27679895-9861E705-449A-40A9-A11D-F9B3A6CD42C0 Q27682550-E9092E64-D5A7-42CB-A9C1-81EECBDE0C9C Q27688045-9D4F3CBF-BE64-4236-AA7A-DE6F430B4C96 Q28072407-65EC9733-060B-44DC-BAE5-2B6A651B5F39 Q28547051-1303E810-310C-4FFD-B2FE-E174FF18576F Q28818769-066EF861-7B13-4CA5-A53B-768FF4A0BC8A Q30511916-A27BF6D9-FB2E-4A76-8D43-120A17D8A881 Q33599961-D2FC97C7-D802-486C-BC5F-1A063C4B60BC Q33876210-EAF9E480-7048-4414-90D0-669A8E221CD3 Q33884270-B695A636-4CBC-42B4-8ED9-A4256060531E Q34380877-85BF98F8-84F7-44BD-93C1-5A9F2332A87A Q34445379-14C71134-FB31-4DC1-B368-B0E465D36E27 Q34471346-CF21A9DF-838F-4F72-89EE-FC7675846CDE Q34474034-451C63CD-89AF-41AB-9235-686DAF3C4AD9 Q34507603-BC33E7B6-7654-4CCB-901E-5AF5503CBC45 Q35692461-F3A3235C-16F6-4A1E-9CA2-F2E7AB499F0E Q35748820-37D91498-B6AB-4D0F-8E29-3FC2A67D9C02 Q35780298-2E35DA28-9644-4CA3-9472-8FD85D652266 Q35799445-F16C844C-54C6-4030-A932-C907D41696D4 Q35954982-C11368CE-15A5-42DF-8E49-4E486C1E6E55 Q36040901-D3C0A89B-BD16-4BD1-A785-34A7DCC4EDA7 Q36254454-B54D2AA1-E3A0-40D3-A332-591842CF284F Q36316025-179F256B-3D93-4193-8346-8AA553B73D3B Q36333938-945DBFF0-3D83-47B1-9FBB-E0699FD2AD20 Q36393594-D21721F1-F50A-4C0A-8899-FDB0E1216C49 Q37367962-D9D78665-9DBF-4B17-834E-CA19E9657088 Q37394193-7ECABF38-8BB1-421F-808E-68E55D30C43D Q38024123-B8E88F16-A5B1-4EEB-BB0B-7A18072641DD Q38075818-DFF8835C-3DB7-49EF-B747-6E2F74221D3D Q38137253-FE52248E-845F-4C31-ADBB-94AA0E7A880D Q38157763-A9A22A68-6EAA-4D18-9E7C-91D2381DB8D1 Q38221015-CCF4C420-7208-4F15-A247-501E73E66989 Q38236706-066DC693-338E-412D-A32D-58005FFCAC02 Q38243344-96F5C4B7-F8BC-4202-8606-B30C097BD991 Q38255176-ABE5F175-3354-4B29-B475-A236FAA7F3E8

P2860

Adnectins: engineered target-binding protein therapeutics

http://www.wikidata.org/entity/Q33743756

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Adnectins: engineered target-binding protein therapeutics

@ast

Adnectins: engineered target-binding protein therapeutics

@en

type

label

Adnectins: engineered target-binding protein therapeutics

@ast

Adnectins: engineered target-binding protein therapeutics

@en

prefLabel

Adnectins: engineered target-binding protein therapeutics

@ast

Adnectins: engineered target-binding protein therapeutics

@en

P1433

Q33743756-822C8909-43A2-400F-8CB5-486D204547FE

P1476

Q33743756-3DCE65ED-919E-4EA8-A5A3-54394C95CFC2

P2093

Q33743756-68734E06-5ED7-4977-B8F1-17046865C050

P275

Q33743756-299F972A-F040-4562-A304-DBA07F90CA11

P2860

Q33743756-03DAC06D-AB4C-4F47-B5BF-7110D5C12165

Q33743756-08494CE3-0E5B-452C-9337-DBBA3F13B8CB

Q33743756-0C12B368-6469-4E53-8BB0-5A99EBF083B3

Q33743756-0C1B1D25-D0F1-49A3-A85F-60CB4FCFB43C

Q33743756-1221525A-8C72-41F9-852A-31FD55277C7E

Q33743756-1E99825B-9E92-4D8F-A211-3F08B1B23CAA

Q33743756-1F611859-EF14-4095-B53D-9B6FD52421EA

Q33743756-238C2314-09E1-45F6-80F4-2A554046121C

Q33743756-25C963A1-8E5B-4520-A0F5-ED510A1CDC34

Q33743756-31098C19-8252-41A5-8DBF-A234F3A62DC1

P304

Q33743756-9048E04E-891B-4718-B51F-4E331E0B4C45

P31

Q33743756-5749D733-199C-443A-B7A4-D0B3D5296437

Q33743756-F6F1CB93-B3F1-472A-8E7C-4898C0866C83

P356

Q33743756-3C1CDAF8-FFDA-4632-8966-D17893667E8D

P433

Q33743756-68436C15-34B6-4F67-9BBD-C86DBF4803D8

P478

Q33743756-B5085162-B9D5-4C12-99F6-8740C27C7D67

P577

Q33743756-1E70EF93-7566-4F45-9640-05DFEE223A05

Q33743756-387F20E4-A16C-4C4E-BA05-F51A7BEA970A

P5875

Q33743756-C2FFD8A1-4673-4516-9E93-35EEADB6BC95

P698

Q33743756-10A85D77-4F40-4721-9510-B51171A98388

P921

Q33743756-16F93C8B-AC2B-4305-A70E-303227A603A0

Q33743756-30C03F87-D84B-4AAE-BFCF-F53F68EBFD68

Q33743756-81E78D8D-DE08-40DB-94FA-32DB3AA7CA7C

Q33743756-91B8E448-36C7-469F-89A6-EECE071A418D

P932

Q33743756-34F9ACCD-4CED-450E-9FAA-DF4A505785E6

P356

P1433

Protein Engineering Design and Selection

P1476

Adnectins: engineered target-binding protein therapeutics

@en

P2093

D Lipovsek

http://www.w3.org/2001/XMLSchema#string

P275

P2860

The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions

Continuous cultures of fused cells secreting antibody of predefined specificity

Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor.

High-affinity single-domain binding proteins with a binary-code interface

A Dominant Conformational Role for Amino Acid Diversity in Minimalist Protein–Protein Interfaces

General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold

A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain

Crystal structure of the tenth type III cell adhesion module of human fibronectin

2.0 A crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region

Crystallographic structure of an intact IgG1 monoclonal antibody

P304

3-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/PROTEIN/GZQ097

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47742412

http://www.w3.org/2001/XMLSchema#string

P698

21068165

http://www.w3.org/2001/XMLSchema#string

P921

fibrous protein

membrane proteins

biomedical investigative technique

P932

3003446

http://www.w3.org/2001/XMLSchema#string